The Naama Aviram Lab
Research
Like any other organism, bacteria are constantly exposed to pathogenic threats, such as viruses and plasmids. The Aviram Lab is interested in understanding how bacterial cells protect themselves from invaders, focusing particularly on the CRISPR-Cas adaptive immune system. CRISPR-Cas systems have a remarkable capability to form immunological memories by integrating short segments of invading genomes, called “spacers” into the CRISPR locus in the genome of the bacterial host. These spacers are later transcribed into crRNA that are loaded on Cas nucleases to target them to cleave and block recurring infections.
Our work focuses on the type III CRISPR-Cas system, one of the most complex and understudied CRISPR-Cas types. We have previously demonstrated that this system is capable of acquiring new spacers by two distinct modes—one arising from transcribed regions and the other from exposed dsDNA ends. This suggests the existence of underlying mechanisms that link the spacer-acquisition machinery to the bacterial transcription apparatus and to processes ensuring DNA integrity. Using genetics, genomics, high-throughput screening and live fluorescence imaging, our research examines how these spacers are acquired, regulated, and maintained, even when they pose a risk of the bacterial host itself. By exploring these molecular dynamics, we hope to expand our understanding of bacterial defense and its impact on bacterial physiology, adaptability, and evolution.
Publications Highlights
Aviram N*^, Shilton AK*, Reis BS, Brivanlou A, Marraffini LA^ (2024). Cas10 relieves host growth arrest to facilitate spacer retention during type III-A CRISPR-Cas immunity. Cell Host & Microbe 32(12), 2050-2062.
Aviram N^, Thornal AN, Zeevi David, Marraffini LA^ (2022). Different modes of spacer acquisition by the Staphylococcus epidermidis type III-A CRISPR-Cas system. Nucleic Acid Research 50, 1661-1672.
People
Naama Aviram, PhD
Assistant Professor
- The Aviram Lab investigates the molecular mechanisms that protect microorganisms from their own pathogenic invaders.
- PhD, Weizmann Institute of Science (2017)
- Postdoc, The Rockefeller University (2024)
- aviramn@mskcc.org
- Email Address
Members
- BS, University of Toronto
- Cancer Biology
Achievements
- The Tri-Institutional Breakout Prize for Junior Investigators (2024)
- K99/R00 Pathway to Independence Award, NIGMS NIH (2023-2028)
- Simons Society of Fellows Postdoctoral Fellowship (2018-2022)
- EMBO Long-Term Postdoctoral Fellowship (2018)
- The Israeli National Postdoctoral Award for Advancing Women in Science (2017-2020)
Lab News & Events
Upcoming event
Cellular Adaptation to Cancer Therapy and the Tumor Microenvironment
Memorial Sloan Kettering Cancer Center
1275 York Avenue
Room M-107
New York, NY 10065
Open Positions
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
Get in Touch
-
Lab Head Email
Disclosures
Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.
MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.
Naama Aviram discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.